Press Releases

03.03.2015

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

02.26.2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

02.24.2015

Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diphtheria And Pertussis (Tdap) Vaccines In Adolescents

02.20.2015

FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)

02.13.2015

Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)

02.12.2015

Safety and Efficacy of ELELYSO® (taliglucerase alfa) for Injection in Pediatric Patients with Type 1 Gaucher Disease in Long-term Outcome Study Presented at the WORLDSymposium 2015

02.09.2015

Pfizer Commences $5 Billion Accelerated Share Repurchase

02.09.2015

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Investor Conference

02.05.2015

University of Dundee signs agreement with Pfizer Inc. to research potential new therapies for the treatment of Cystic Fibrosis.

02.05.2015

Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer's Proposed Acquisition of Hospira

02.04.2015

Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ® (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis

02.04.2015

Pfizer Marks World Cancer Day With Grant To Union For International Cancer Control To Address The Needs Of Metastatic Breast Cancer Patients